Suppr超能文献

炎症和致动脉粥样硬化血脂异常对家族性高胆固醇血症患者及其家庭成员亚临床颈动脉粥样硬化的协同作用:超声评估

Synergistic Effects of Inflammation and Atherogenic Dyslipidemia on Subclinical Carotid Atherosclerosis Assessed by Ultrasound in Patients with Familial Hypercholesterolemia and Their Family Members.

作者信息

Lin Po-Chih, Chen Chung-Yen, Wu Charlene, Su Ta-Chen

机构信息

Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei 100225, Taiwan.

Department of Environmental and Occupational Medicine, National Taiwan University Hospital, Taipei 100225, Taiwan.

出版信息

Biomedicines. 2022 Feb 2;10(2):367. doi: 10.3390/biomedicines10020367.

Abstract

Low-density lipoprotein cholesterol (LDL-C) and total to high-density lipoprotein cholesterol (TC/HDL-C) ratio are both common risk factors for atherosclerotic cardiovascular diseases (ASCVDs). However, whether high-sensitivity C-reactive protein (hsCRP) has synergistic or attenuated effects on atherogenic dyslipidemia remains unclear. We investigated subclinical carotid atherosclerosis in patients with familial hypercholesterolemia (FH) and their family members. A total of 100 families with 761 participants were prospectively studied. Participants were categorized into four groups according to atherogenic dyslipidemia and inflammatory biomarkers. The group with LDL-C ≥ 160 mg/dL (or TC/HDL-C ratio ≥ 5) combined with hsCRP ≥ 2 mg/L have a thicker carotid intima-media thickness (CIMT) in different common carotid artery (CCA) areas and a higher percentage of high plaque scores compared with other subgroups. Multivariate logistic regression analysis revealed a significantly higher adjusted odds ratio (aOR) for thicker CIMT of 3.56 (95% CI: 1.56-8.16) was noted in those with concurrent LDL-C ≥ 160 mg/dL and hsCRP ≥ 2 mg/L compared with the group with concurrent LDL-C < 160 mg/dL and hsCRP < 2 mg/L. Our results demonstrated that systemic inflammation, in terms of higher hsCRP levels ≥ 2 mg/L, synergistically contributed to atherogenic dyslipidemia of higher LDL-C or a higher TC/HDL-C ratio on subclinical atherosclerosis.

摘要

低密度脂蛋白胆固醇(LDL-C)以及总胆固醇与高密度脂蛋白胆固醇之比(TC/HDL-C)均为动脉粥样硬化性心血管疾病(ASCVD)的常见危险因素。然而,高敏C反应蛋白(hsCRP)对致动脉粥样硬化性血脂异常是具有协同作用还是减弱作用仍不清楚。我们对家族性高胆固醇血症(FH)患者及其家庭成员的亚临床颈动脉粥样硬化情况进行了研究。前瞻性地研究了总共100个家庭的761名参与者。根据致动脉粥样硬化性血脂异常和炎症生物标志物将参与者分为四组。与其他亚组相比,LDL-C≥160mg/dL(或TC/HDL-C比值≥5)且hsCRP≥2mg/L的组在不同颈总动脉(CCA)区域的颈动脉内膜中层厚度(CIMT)更厚,高斑块评分的百分比更高。多因素逻辑回归分析显示,与LDL-C<160mg/dL且hsCRP<2mg/L的组相比,LDL-C≥160mg/dL且hsCRP≥2mg/L的组CIMT增厚的调整优势比(aOR)显著更高,为3.56(95%CI:1.56 - 8.16)。我们的结果表明,就hsCRP水平≥2mg/L而言,全身炎症对亚临床动脉粥样硬化中较高LDL-C或较高TC/HDL-C比值的致动脉粥样硬化性血脂异常具有协同作用。

相似文献

5

本文引用的文献

1
Colchicine in Patients with Chronic Coronary Disease.秋水仙碱治疗慢性冠心病
N Engl J Med. 2020 Nov 5;383(19):1838-1847. doi: 10.1056/NEJMoa2021372. Epub 2020 Aug 31.
3
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.心梗后小剂量秋水仙碱的疗效和安全性。
N Engl J Med. 2019 Dec 26;381(26):2497-2505. doi: 10.1056/NEJMoa1912388. Epub 2019 Nov 16.
5
Investigating the association between familial hypercholesterolemia and perceived depression.
Atheroscler Suppl. 2019 Mar;36:31-36. doi: 10.1016/j.atherosclerosissup.2019.01.007. Epub 2019 Jan 29.
6
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.低剂量甲氨蝶呤预防动脉粥样硬化事件。
N Engl J Med. 2019 Feb 21;380(8):752-762. doi: 10.1056/NEJMoa1809798. Epub 2018 Nov 10.
9
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.卡那奴单抗治疗动脉粥样硬化疾病的抗炎疗法。
N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验